Valmark Advisers Inc. Sells 618 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Valmark Advisers Inc. trimmed its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 14.8% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 3,555 shares of the biopharmaceutical company’s stock after selling 618 shares during the quarter. Valmark Advisers Inc.’s holdings in Gilead Sciences were worth $298,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Diversify Advisory Services LLC bought a new position in shares of Gilead Sciences during the first quarter valued at $316,000. Mission Wealth Management LP lifted its stake in Gilead Sciences by 3.0% during the 1st quarter. Mission Wealth Management LP now owns 12,454 shares of the biopharmaceutical company’s stock valued at $912,000 after acquiring an additional 368 shares during the period. Resonant Capital Advisors LLC boosted its holdings in shares of Gilead Sciences by 12.6% during the 1st quarter. Resonant Capital Advisors LLC now owns 3,050 shares of the biopharmaceutical company’s stock valued at $223,000 after acquiring an additional 342 shares during the last quarter. Stone Point Wealth LLC raised its holdings in shares of Gilead Sciences by 3.5% during the first quarter. Stone Point Wealth LLC now owns 35,472 shares of the biopharmaceutical company’s stock valued at $2,598,000 after purchasing an additional 1,214 shares during the last quarter. Finally, Fortem Financial Group LLC lifted its position in Gilead Sciences by 17.9% during the first quarter. Fortem Financial Group LLC now owns 9,496 shares of the biopharmaceutical company’s stock valued at $696,000 after purchasing an additional 1,444 shares during the period. 83.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have commented on the stock. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $70.00 target price on shares of Gilead Sciences in a research report on Monday, September 16th. Raymond James upgraded Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.00 price objective for the company in a research report on Monday, July 8th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research report on Thursday, August 15th. BMO Capital Markets boosted their price target on Gilead Sciences from $85.00 to $94.00 and gave the company an “outperform” rating in a research note on Thursday, October 17th. Finally, Wells Fargo & Company upgraded shares of Gilead Sciences from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $78.00 to $100.00 in a research note on Monday, October 7th. Ten equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and three have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $86.85.

Insider Buying and Selling

In other Gilead Sciences news, insider Johanna Mercier sold 29,357 shares of Gilead Sciences stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the transaction, the insider now directly owns 78,127 shares of the company’s stock, valued at $6,545,480.06. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total transaction of $167,660.00. Following the sale, the insider now directly owns 100,189 shares in the company, valued at $8,398,843.87. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Johanna Mercier sold 29,357 shares of Gilead Sciences stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the transaction, the insider now owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 36,847 shares of company stock worth $3,033,340. Insiders own 0.16% of the company’s stock.

Gilead Sciences Price Performance

Shares of Gilead Sciences stock opened at $88.82 on Friday. The company has a quick ratio of 0.95, a current ratio of 1.14 and a debt-to-equity ratio of 1.18. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $89.74. The stock’s 50-day simple moving average is $83.54 and its 200-day simple moving average is $73.97. The company has a market capitalization of $110.66 billion, a price-to-earnings ratio of 246.72, a PEG ratio of 3.07 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping the consensus estimate of $1.61 by $0.40. The business had revenue of $6.95 billion during the quarter, compared to the consensus estimate of $6.64 billion. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. As a group, analysts expect that Gilead Sciences, Inc. will post 3.76 earnings per share for the current fiscal year.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.